Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
2.
Clin Dermatol ; 39(3): 418-423, 2021.
Article in English | MEDLINE | ID: covidwho-1491857

ABSTRACT

Italy was among the world's earliest and most affected countries by coronavirus disease 2019 (COVID-19). We report the Italian experience with the pandemic. The dermatologic community immediately reduced any type of activities to 80% to 90% of outpatient consultations, both in public hospitals and in private offices. The Italian Society of Dermatology and Sexually Transmitted Diseases and the Italian Forensic Dermatologic Society supported the dermatologic community by reporting recommendations in newsletters (vademecum) regarding the routine management of dermatologic patients either in the hospital or private setting. We have provided an overview of the skin manifestations from the pandemic, including the consequences of the misuse of safety measures. We also have evaluated the recently developed research projects on patients treated with biologics for psoriasis, atopic dermatitis, and hidradenitis suppurativa, as well as on the registries regarding various skin diseases affected by COVID-19.


Subject(s)
COVID-19 , Hidradenitis Suppurativa , Hidradenitis Suppurativa/epidemiology , Humans , Italy/epidemiology , Pandemics , SARS-CoV-2
6.
J Drugs Dermatol ; 20(8): 868-873, 2021 Aug 01.
Article in English | MEDLINE | ID: covidwho-1359537

ABSTRACT

The Symposium on Hidradenitis Suppurativa Advances (SHSA) is a joint meeting of the United States Hidradenitis Suppurativa Foundation (HSF) and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This annual cross-disciplinary meeting brings together experts from around the world in an opportunity to discuss the most recent advances in the study of hidradenitis suppurativa (HS). The fifth annual meeting was held virtually on 9-11 October 2020. A record 347 attendees, including 79 people with HS, from 20 different countries attended. Key take-home points included: Clinicians can optimize each visit by listening, provide education, and discuss treatments; a patient decision aid for HS (HS-PDA) is a freely available tool (www.informed-decisions.org); COVID-19 severity in HS patients was not different for patients treated with/without a biologic; comorbidity screening recommendations will be published soon; neutrophil extracellular traps (NETs) may play a role in HS; memory B cells, T helper 1 cytokines, and interleukin 1 signaling contributes to HS pathogenesis and are targets for new therapies; novel therapies are showing promise including a new JAK1 inhibitor (INCB054707) and brodalumab; and HS-specific outcome measures have emerged to better monitor disease severity, flare, and progression including a patient reported measure (HiSQOL) and an HS-specific investigator global assessment. J Drugs Dermatol. 2021;20(8):868-873. doi:10.36849/JDD.5836.


Subject(s)
Hidradenitis Suppurativa , COVID-19 , Canada , Comorbidity , Congresses as Topic , Cytokines , Decision Support Techniques , Disease Progression , Extracellular Traps , Hidradenitis Suppurativa/diagnosis , Hidradenitis Suppurativa/therapy , Humans , Patient Reported Outcome Measures , Severity of Illness Index
9.
Clin Dermatol ; 39(1): 52-55, 2021.
Article in English | MEDLINE | ID: covidwho-1300690

ABSTRACT

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, medical professionals have been overwhelmed by questions beyond the infection itself. In dermatology practice, clinicians have been facing difficulties about the management of chronic immune-mediated skin diseases. Issues arose, such as the grade of immunosuppression or immunomodulation, discontinuation or modification of treatment, and initiation of new treatments. In this comprehensive review, we present the current evidence about the course and management of chronic inflammatory dermatoses during the COVID-19 pandemic, focusing on psoriasis, atopic dermatitis, and hidradenitis suppurativa.


Subject(s)
Biological Products/therapeutic use , COVID-19/epidemiology , Dermatitis, Atopic/drug therapy , Hidradenitis Suppurativa/drug therapy , Psoriasis/drug therapy , COVID-19/prevention & control , Chronic Disease , Dermatitis, Atopic/immunology , Hidradenitis Suppurativa/immunology , Humans , Prognosis , Psoriasis/immunology , SARS-CoV-2
10.
Exp Dermatol ; 30 Suppl 1: 23-26, 2021 06.
Article in English | MEDLINE | ID: covidwho-1290136

ABSTRACT

Hidradenitis suppurativa (HS) in South-East Asia and East Asia shows distinct clinical, environmental, physiological and likely genetic differences compared with the West. A male predominance is present, which may be due to differences in smoking habits. Involvement of the buttocks is common in East Asian patients, while the axillae are most commonly affected in South-East Asian patients. Metabolic comorbidities are prevalent in South-East Asian and East Asian HS patients. A family history of HS is less common than noted in Western populations. Asian ethnic subgroups deserve further study.


Subject(s)
Hidradenitis Suppurativa/epidemiology , Asia, Southeastern/epidemiology , Far East/epidemiology , Female , Hidradenitis Suppurativa/physiopathology , Humans , Male , Severity of Illness Index , Smoking/epidemiology
11.
Exp Dermatol ; 30 Suppl 1: 18-22, 2021 06.
Article in English | MEDLINE | ID: covidwho-1258931

ABSTRACT

The reported incidence of COVID-19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID-19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID-19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti-COVID-19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS-CoV2 and patients affected by metabolic syndrome constitute a high-risk group for COVID-19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non-living virus anti-SARS-CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.


Subject(s)
COVID-19/complications , Hidradenitis Suppurativa/complications , Hidradenitis Suppurativa/drug therapy , SARS-CoV-2 , Adalimumab/therapeutic use , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/immunology , COVID-19 Vaccines/pharmacology , Cohort Studies , Disease Susceptibility , Europe , Foundations , Hidradenitis Suppurativa/immunology , Humans , Incidence , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Metabolic Syndrome/complications , Metabolic Syndrome/immunology , Pandemics , Severity of Illness Index
15.
Clin Exp Dermatol ; 46(6): 1079-1081, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1189655

ABSTRACT

Remote dermatology consultations largely superseded face-to-face (FTF) consultations during the peak of the COVID-19 pandemic in the UK. Remote examination of patients with hidradenitis suppurativa (HS) brings particular challenges, given the propensity of HS to affect intimate body areas. To understand the impact of remote consultations on the care of patients with HS, a retrospective analysis was conducted of all consultations from 2 April to 29 October 2020 at the HS clinic at Imperial College Healthcare NHS Trust. In this group of patients with HS, 46.3% were black, compared with 7.0% of patients attending general dermatology clinics (P < 0.001). The majority (65.9%) of patients had previously received or were currently taking adalimumab. All consultations were performed by telephone and in 50.7% of the consultations, patients were assessed as having unstable (u)HS, with 81.1% of these uHS episodes leading to a change in pharmacological therapy. The decision-making process was aided by patient-submitted photographs at only 8.1% of consultations involving uHS, for reasons of patient privacy, comfort and data security. The data suggest that HS is an inherently unstable disease despite maximal medical therapy, and this study highlights important reasons for the assessment of patients with HS by FTF consultations where safely possible.


Subject(s)
COVID-19/epidemiology , Hidradenitis Suppurativa/diagnosis , Pandemics , Remote Consultation/methods , Adult , Comorbidity , Female , Follow-Up Studies , Hidradenitis Suppurativa/epidemiology , Humans , Male , Retrospective Studies , SARS-CoV-2 , Severity of Illness Index
18.
Dermatol Online J ; 26(10)2020 Oct 15.
Article in English | MEDLINE | ID: covidwho-908494

ABSTRACT

Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential risk of SARS-CoV-2 infection. This article includes an overview of the up-to-date international and U.S. treatment guidelines for psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne/rosacea; it provides tables summarizing these resources to assist providers and patients in remaining updated regarding recommended treatment modifications during the pandemic (See Tables 1-4).


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Dermatitis, Atopic/drug therapy , Hidradenitis Suppurativa/drug therapy , Pneumonia, Viral/epidemiology , Psoriasis/drug therapy , Rosacea/drug therapy , Biological Products/therapeutic use , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/transmission , Humans , Immunosuppressive Agents , Internationality , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/transmission , SARS-CoV-2 , United States
20.
F1000Res ; 92020.
Article in English | MEDLINE | ID: covidwho-769918

ABSTRACT

Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients' growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.


Subject(s)
Hidradenitis Suppurativa/diagnosis , Hidradenitis Suppurativa/therapy , Female , Humans , Male , Prospective Studies , Quality of Life , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL